Latest News and Press Releases

Partial remissions and complete metabolic responses in PD-1/PD-L1-resistant cancersFirst-in-class multi-checkpoint inhibitor with robust efficacy and safetyCombination arm with pembrolizumab...

Recognition highlights company’s antithrombotic platform and late-stage programs designed to transform care in oncology and inflammation driven diseases

GAITHERSBURG, Md., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty...

GAITHERSBURG, Md., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty...

Cancer-fighting immunosuppressive agents shown to disrupt telomeres and suspend growth of cancer cells  CHICAGO , Aug. 13, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA)...

Boston, July 10, 2025 (GLOBE NEWSWIRE) -- According to the latest study from BCC Research, the “Current R&D Status of Chimeric Antigen Receptor (CAR) T-Cell Therapy Market” is expected to grow...

GAITHERSBURG, Md., June 12, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty...

Boston, June 05, 2025 (GLOBE NEWSWIRE) -- As cancer prevalence continues to rise globally, nanotechnology in cancer treatment is emerging as a transformative force in oncology. Leveraging nanoscale...

GAITHERSBURG, Md., June 04, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty...

GAITHERSBURG, Md., May 15, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty...